Clinical Trial Update: Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study [Phase 4]

View source ↗

Summary

A Phase 4 rollover study evaluating crizanlizumab in sickle cell disease patients who completed a prior Novartis-sponsored crizanlizumab trial; the trial is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ADAKVEO (crizanlizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease | Phase 4 | Status: RECRUITING